CoChat

A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin

Berne, C., the Orlistat Swedish Type 2 diabetes Study Group · 2005 · Diabetic Medicine
Cited by 112

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Aims To assess the effects of orlistat vs. placebo, in combination with a weight management programme, on weight loss and metabolic control in obese patients with Type 2 diabetes. Methods Patients treated with either metformin alone or metformin in combination with sulphonylurea were randomized to double‐blind treatment with orlistat or placebo (120 mg) three times daily, combined with a mildly reduced calorie diet and a weight management programme for 52 weeks. Changes in body weight, anthropometry, glycaemic control and lipid profile were assessed. Results After 52 weeks, orlistat‐treated patients achieved an almost threefold greater reduction in weight compared with placebo recipients (−5.0% vs. −1.8%; P < 0.0001). The decrease in waist circumference was significantly greater with orlistat than placebo (−4.8 cm vs. −2.8 cm; P = 0.0022). Orlistat treatment was also associated with significantly greater reductions in haemoglobin A 1c (−1.1% vs. −0.2%; P < 0.0001), fasting plasma glucose (−1.9 mmol/l vs. −0.3 mmol/l; P < 0.0001), total cholesterol (−0.2 mmol/l vs. 0.1 mmol/l; P = 0.03) and apolipoprotein B (−0.08 g/l vs. 0.01 g/l; P = 0.0085) and greater improvements in beta‐cell function (P = 0.031) and insulin resistance (P = 0.001) assessed using the homeostasis model assessment (HOMA). Similar results were obtained for subgroups of patients treated with metformin alone or metformin in combination with sulphonylurea. Orlistat treatment reduced the requirement for anti‐diabetic medication more than placebo. Conclusions Orlistat, in combination with a reduced calorie diet and a weight management programme, promotes weight loss and clinically relevant improvements in glycaemic control and other cardiovascular risk factors in obese patients with Type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2004.01474.x

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 112

Metadata

Authors
Berne, C., & the Orlistat Swedish Type 2 diabetes Study Group
Venue
Diabetic Medicine
Publisher
Wiley
Published
2005-01-25
Volume
22
Issue
5
Pages
612-618
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2126177048
Cited by
112
References
15
FWCI
5.16
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. https://app.cochat.ai/papers/10.1111/j.1464-5491.2004.01474.x
The paper
Berne, C., & the Orlistat Swedish Type 2 diabetes Study Group. (2005). A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2004.01474.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.